Prevalence of MAFLD in Patients With Type 2 Diabetes in Jiangsu Province of China

NCT05597709 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2900

Last updated 2022-10-28

No results posted yet for this study

Summary

In 2019, the number of patients with diabetes was about 463 million in the world, accounting for 8.3% of the total population, and it is expected to rise to 578 million (9.2%) by 2030 and 700 million (9.6%) by 2045. According to the WHO diagnostic criteria, the prevalence of diabetes among adults in China from 2015 to 2017 was 11.2%, of which over 90% were type 2 diabetes mellitus (T2DM). The global prevalence of non-alcoholic fatty liver disease (NAFLD) is also very high, which was approximately 25% in 2016. The prevalence of NAFLD may continue to rise. NAFLD is often accompanied by clinical manifestations of metabolic syndrome, such as obesity, T2DM, hyperlipidemia and hypertension.

Conditions

  • Type 2 Diabetes Mellitus in Remission
  • Metabolic Associated Fatty Liver Disease

Interventions

PROCEDURE

Ultrasound attenuation parameter measurement, fasting blood glucose and fasting insulin determination

Eligible participants will receive ultrasound attenuation parameter with iLivTouch, fasting blood glucose and fasting insulin determination

Sponsors & Collaborators

  • Zhongda Hospital

    collaborator OTHER
  • Suzhou Municipal Hospital

    collaborator OTHER
  • Suzhou Fifth People's Hospital

    collaborator UNKNOWN
  • Xuzhou Mining Group General Hospital

    collaborator UNKNOWN
  • Nantong First People's Hospital

    collaborator OTHER
  • Changzhou Second People's Hospital

    collaborator UNKNOWN
  • Huaian Second People's Hospital

    collaborator UNKNOWN
  • Huaian Hospital

    collaborator UNKNOWN
  • Taizhou Jiangyan Traditional Chinese Medicine Hospital

    collaborator UNKNOWN
  • Yangzhou Jiangdu People's Hospital

    collaborator UNKNOWN
  • Huaian Xuyi County People's Hospital

    collaborator UNKNOWN
  • Wuxi Hisky Medical Technology Co Ltd

    lead INDUSTRY

Principal Investigators

  • Ling Li, Professor · Zhongda Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2023-06-01
Completion
2027-06-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05597709 on ClinicalTrials.gov